The Swedish pharma company Orexo and biotech firm Abera Bioscience announced today that they have joined forces to develop ...

Mesoblast has received FDA approval for Ryoncil, becoming the first and only cell therapy of its kind to be available in the US. Ryoncil (remestemcel-L-rknd) has been granted approval by the FDA for ...

The partnership revolves around Muna Therapeutics’ technology platform, which employs a spatial multi-omics approach to identify and validate new drug targets for neurodegenerative diseases. GSK and ...

The sickle cell gene therapies developed by Bluebird Bio and Vertex will be the first to be offered under the new scheme. A major issue with gene and cell therapies is the upfront cost. While these ...

The potential $2.9 billion deal stands the New Jersey company in good stead after recent disappointing results in its ALS program. PTC Therapeutics announced this week that it has made a deal with ...

Mesoblast has received FDA approval for Ryoncil, becoming the first and only cell therapy of its kind to be available in the US.

The biologic treatment missed the primary endpoint, but did show some improvements in those given the drug and may be better for treating some subgroups than others. Prasinezumab was originally ...

The Danish biotech company Antag Therapeutics announced yesterday that it had raised €80 million ($84 million) in a Series A financing round to boost the clinical development of its next-generation ...

The merger of Nvelop Therapeutics and Chroma Medicine brings together a combination of epigenetic editing and in vivo delivery expertise to develop new genetic medicines. The launch of nChroma is ...

New Alzheimer’s drug tackles early disease progression.